Tharimmune Inc Financials
Financial Health Signals
Tharimmune Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Tharimmune Inc generates $0.89 in operating cash flow (-$10.9M OCF vs -$12.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Tharimmune Inc earns $-908.6 in operating income for every $1 of interest expense (-$12.4M vs $14K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Tharimmune Inc (THAR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Tharimmune Inc reported -$12.2M in net income in fiscal year 2024. This represents a decrease of 30.9% from the prior year.
Tharimmune Inc earned $-9.41 per diluted share (EPS) in fiscal year 2024. This represents an increase of 91.2% from the prior year.
Tharimmune Inc held $3.6M in cash against $0 in long-term debt as of fiscal year 2024.
Tharimmune Inc had 2M shares outstanding in fiscal year 2024. This represents an increase of 123.2% from the prior year.
Tharimmune Inc invested $6.4M in research and development in fiscal year 2024. This represents an increase of 79.6% from the prior year.
THAR Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $278K-49.1% | $546K-8.1% | $594K-74.0% | $2.3M+128.3% | $1000K-2.5% | $1.0M | N/A | $488K |
| SG&A Expenses | $1.8M+39.1% | $1.3M-33.2% | $2.0M+23.3% | $1.6M+15.3% | $1.4M+3.9% | $1.3M | N/A | $1.4M |
| Operating Income | -$2.1M-13.1% | -$1.9M+27.3% | -$2.5M+34.1% | -$3.9M-62.9% | -$2.4M-1.1% | -$2.3M | N/A | -$1.8M |
| Interest Expense | $10K+56.6% | $6K-27.3% | $8K+181.5% | $3K-42.3% | $5K+11.0% | $5K | N/A | $3K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$2.1M-13.3% | -$1.9M+27.0% | -$2.5M+33.0% | -$3.8M-63.3% | -$2.3M-3.1% | -$2.3M | N/A | -$1.8M |
| EPS (Diluted) | $-0.34 | $-0.64+35.4% | $-0.99+59.6% | $-2.45-1.2% | $-2.42 | $-2.55 | N/A | $-39.42 |
THAR Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.7M+204.3% | $2.5M+52.3% | $1.7M-55.4% | $3.7M-54.9% | $8.3M-7.1% | $8.9M-18.8% | $10.9M+245.6% | $3.2M |
| Current Assets | $7.7M+204.3% | $2.5M+52.3% | $1.7M-55.4% | $3.7M-54.9% | $8.3M-7.1% | $8.9M-18.8% | $10.9M+245.6% | $3.2M |
| Cash & Equivalents | $7.6M+239.4% | $2.2M+108.4% | $1.1M-69.8% | $3.6M-54.9% | $7.9M-6.3% | $8.4M-22.9% | $10.9M+306.7% | $2.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.5M-28.6% | $2.2M-12.6% | $2.5M+2.6% | $2.4M+54.4% | $1.6M-14.9% | $1.8M+1.3% | $1.8M+28.7% | $1.4M |
| Current Liabilities | $1.5M-28.6% | $2.2M-12.6% | $2.5M+2.6% | $2.4M+54.4% | $1.6M-14.9% | $1.8M+1.3% | $1.8M+28.7% | $1.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $6.2M+1575.4% | $367K+145.1% | -$815K-162.3% | $1.3M-80.5% | $6.7M-5.0% | $7.0M-22.8% | $9.1M+419.7% | $1.8M |
| Retained Earnings | -$43.4M-5.1% | -$41.3M-4.7% | -$39.4M-6.9% | -$36.9M-26.0% | -$29.3M-8.6% | -$27.0M-9.1% | -$24.7M-11.1% | -$22.2M |
THAR Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.9M-62.4% | -$1.1M+57.5% | -$2.7M+11.4% | -$3.0M-39.2% | -$2.2M+22.9% | -$2.8M-99.6% | -$1.4M-55.7% | -$909K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $7.2M+212.9% | $2.3M+1023.0% | $206K-88.7% | $1.8M+10.4% | $1.6M+419.6% | $317K-96.7% | $9.7M+3257.4% | -$306K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
THAR Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -27.3%+46.0pp | -73.3%+79.7pp | -153.0%-80.7pp | -72.3%-44.1pp | -28.2%-2.8pp | -25.4% | N/A | -57.5% |
| Current Ratio | 4.98+3.8 | 1.17+0.5 | 0.67-0.9 | 1.54-3.7 | 5.28+0.4 | 4.84-1.2 | 6.03+3.8 | 2.25 |
| Debt-to-Equity | 0.25-5.6 | 5.89+8.9 | -3.04-4.9 | 1.85+1.6 | 0.23-0.0 | 0.26+0.1 | 0.20-0.6 | 0.80 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Tharimmune Inc profitable?
No, Tharimmune Inc (THAR) reported a net income of -$12.2M in fiscal year 2024.
What is Tharimmune Inc's earnings per share (EPS)?
Tharimmune Inc (THAR) reported diluted earnings per share of $-9.41 for fiscal year 2024. This represents a 91.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Tharimmune Inc's operating cash flow?
Tharimmune Inc (THAR) generated -$10.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Tharimmune Inc's total assets?
Tharimmune Inc (THAR) had $3.7M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Tharimmune Inc spend on research and development?
Tharimmune Inc (THAR) invested $6.4M in research and development during fiscal year 2024.
How many shares does Tharimmune Inc have outstanding?
Tharimmune Inc (THAR) had 2M shares outstanding as of fiscal year 2024.
What is Tharimmune Inc's current ratio?
Tharimmune Inc (THAR) had a current ratio of 1.54 as of fiscal year 2024, which is generally considered healthy.
What is Tharimmune Inc's debt-to-equity ratio?
Tharimmune Inc (THAR) had a debt-to-equity ratio of 1.85 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Tharimmune Inc's return on assets (ROA)?
Tharimmune Inc (THAR) had a return on assets of -327.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Tharimmune Inc's cash runway?
Based on fiscal year 2024 data, Tharimmune Inc (THAR) had $3.6M in cash against an annual operating cash burn of $10.9M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Tharimmune Inc's Piotroski F-Score?
Tharimmune Inc (THAR) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Tharimmune Inc's earnings high quality?
Tharimmune Inc (THAR) has an earnings quality ratio of 0.89x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Tharimmune Inc cover its interest payments?
Tharimmune Inc (THAR) has an interest coverage ratio of -908.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.